Plasma Protein Lipofuscin-like Fluorophores in Men with Coronary Artery Disease Treated with Statins

Background Lipid oxidation products react with protein to produce lipofuscin-like fluorophores (P-LLF) and modified apolipoprotein B that is an important element of the atherogenic properties of oxidized low-density lipoprotein (oxLDL). The aim of this study was to compare plasma concentrations of P...

Full description

Saved in:
Bibliographic Details
Published in:Archives of medical research 2007-10, Vol.38 (7), p.757-763
Main Authors: Sutherland, Wayne H, Williams, Michael J, de Jong, Sylvia A
Format: Article
Language:English
Subjects:
Aged
Albumin
Apolipoprotein B
Apolipoproteins B - blood
Biomarkers - blood
Coronary artery disease
Coronary Artery Disease - blood
Coronary Artery Disease - drug therapy
Coronary Artery Disease - etiology
Fluorescent Dyes
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Internal Medicine
Lipid Peroxidation
Lipofuscin - blood
Lipofuscin-like fluorophores
Lipoproteins, LDL - blood
Male
Middle Aged
Oxidative Stress
Oxidized LDL
Serum Albumin - analysis
Statins
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Lipid oxidation products react with protein to produce lipofuscin-like fluorophores (P-LLF) and modified apolipoprotein B that is an important element of the atherogenic properties of oxidized low-density lipoprotein (oxLDL). The aim of this study was to compare plasma concentrations of P-LLF between men with coronary artery disease (CAD) treated with statin drugs and healthy controls and to identify determinants of P-LLF. Methods Plasma markers of protein modification including P-LLF and oxidized low-density lipoprotein-4E6 (oxLDL-4E6), low-density lipoprotein-conjugated dienes (LDL-CD), lipid peroxides, apolipoprotein B, and serum albumin were measured in 24 men with CAD who were receiving statin therapy and 20 healthy men in the same age range. Results Plasma P-LLF (+23%, p = 0.001) was significantly higher and plasma oxLDL-4E6 (–33%, p
ISSN:0188-4409
1873-5487
DOI:10.1016/j.arcmed.2007.04.004